Johnson & Johnson: The safety data is encouraging, and the findings suggest that as this combination enters phase 3, it is expected to achieve outpatient administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.